When hospitals overcharge insurers for drugs they bought at deep 340B discounts, taxpayers, employers, and insured patients foot the bill.

This contributor column discusses a recent study that shows the 340B Program’s explosive growth is overwhelmingly due to utilization increases, not price. Payers have struggled with the increasing ...

On July 31, 2025, the Health Resources and Services Administration (HRSA) released long-awaited guidance establishing a 340B Rebate Model Pilot Program (Pilot Program). The announcement marks a ...

B 2026 tracking litigation highlights drugmaker mandates and legal challenges reshaping hospital drug pricing and compliance risks.

The federal 340B Drug Pricing Program, which requires pharmaceutical manufacturers participating in Medicaid to sell outpatient drugs at discounted prices to healthcare organizations that care for ...

With post-pandemic Medicaid enrollments on the decline and expected to fall further, revenue cycle leaders warn that ...

On July 31, 2025, the Health Resources and Services Administration (HRSA), Office of Pharmacy Affairs (OPA) issued a 340B Drug Pricing Program notice (the “Notice”) announcing the launch of a ...

The pilot is a significant departure from the current model, which gives hospitals upfront discounts for some drugs. The program has proved a flash point between drugmakers and providers, as ...

The 340B Drug Pricing Program allows certain medical facilities to buy drugs at a discount to support care for low-income patients. Rhode Island's new law, Chapter 288, prevents drug makers from ...

When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...

Nevada hospitals and clinics face challenges as drug manufacturers restrict access to a federal discount drug program, ...